Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Provides Update on COVID-19 Impact and Preliminary Revenue Estimate for First Quarter 2020
SOUTH SAN FRANCISCO, Calif. , April 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today provided an update on the impact of the COVID-19 pandemic on its business and
View HTML
Toggle Summary Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia
SOUTH SAN FRANCISCO, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm ® CyTOF ® technology was used in a clinical study
View HTML
Toggle Summary Consortium of Medical Schools Led by Mount Sinai Fast-Tracking COVID-19 Detection Test Utilizing Fluidigm Microfluidics Technology
Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19 SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry
Fluidigm’s First Mass Cytometry Center of Excellence in Singapore and Southeast Asia for Advancement of Highly Multiplexed Tissue Imaging in Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
View HTML
Toggle Summary Fluidigm Introduces AccuLift Laser Capture Microdissection System to Advance Translational and Clinical Pathology Research
Driving Cell Capture to Insight with Precision, Speed and Simplicity to Accelerate Biomarker and Therapeutic Development SOUTH SAN FRANCISCO, Calif. , March 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life
View HTML
Toggle Summary Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing
Enabling Low-Cost, High-Volume Sequencing of Drug-Resistant Pathogens for Hospital Infection Control and Surveillance SOUTH SAN FRANCISCO, Calif. and HINXTON, United Kingdom , March 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an industry leader in microfluidics technology, and
View HTML
Toggle Summary Fluidigm Completes Acquisition of InstruNor AS
Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools
View HTML
Toggle Summary Fluidigm to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, will
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million ; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates potential clinical value of using Imaging Mass Cytometry Covance selects Fluidigm CyTOF technology to
View HTML
Toggle Summary Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry
New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML